This website requires JavaScript.
Latest Story

Innoplexus opens its AI search platform to COVID-19 research

The platform is already being used by researchers from Germany, USA, and India

Mar 16, 2020 by The Passage Team
Innoplexus opens its AI search platform to COVID-19 research

Innoplexus AG has made its proprietary Ontosight® AI search platform available to medical researchers around the globe to help fight the COVID-19 pandemic with immediate effect. The platform is already being used by researchers from Germany, USA, and India.

'Flattening the curve' necessitates health organizations to take on early measures focused on containment. Various countries, such as Taiwan, Singapore, and Japan, have already succeeded in the containment of the Coronavirus. The use of Big Data analytics, new technologies, and proactive testing all played a central role in making this possible.

Currently, most countries lack this specific expertise and are spending extensive resources on managing mitigation, to make the virus as inoffensive as possible. The better a country's healthcare system can function, the lower the mortality rate, and the higher the share of the population that can be treated.

Innoplexus is committed to enable rapid research for the development of tests and treatments for COVID-19. Today the company announced that it will share an open license for general access to its Ontosight® AI Search platform to help researchers learn more about the novel coronavirus. Government science advisers in a dozen countries are asking to make data on the disease more widely available. Innoplexus is thereby answering the call of the US, Australia, Brazil, Canada, Germany, India, Italy, Japan, New Zealand, Singapore, South Korea, and the UK to make publications available to the research community.

"We hope that we can contribute to the scientific community's research efforts of how the disease functions and spreads, to be able to assist in hypothesis generation as a predictive platform for ongoing and future work to develop therapeutics," said Gunjan Bhardwaj, CEO of Innoplexus AG.

The Passage Team

The Passage is committed to creating in-depth content over technology industry across Asia with a focus on emerging startups in the technology, healthcare, education, food, tech, travel & mobility segments.

Follow The Passage Team